RedHill Biopharma Ltd., a specialty biopharmaceutical company, has received a notification from the Nasdaq Listings Qualifications Department on March 11, 2024, indicating that the company's American Depositary Shares (ADSs) have been trading below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market for the past thirty consecutive business days. This notice does not immediately affect the listing or trading of RedHill's ADSs. The company has until September 9, 2024, to regain compliance with the minimum bid price requirement, as per Nasdaq Listing Rule 5810(c)(3)(A). RedHill's ADSs will continue to trade on The Nasdaq Capital Market, and its operations remain unaffected. RedHill is considering options to address the deficiency and may be eligible for an additional 180-day compliance period if necessary conditions are met.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, has received a notification from the Nasdaq Listings Qualifications Department on March 11, 2024, indicating that the company's American Depositary Shares (ADSs) have been trading below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market for the past thirty consecutive business days. This notice does not immediately affect the listing or trading of RedHill's ADSs. The company has until September 9, 2024, to regain compliance with the minimum bid price requirement, as per Nasdaq Listing Rule 5810(c)(3)(A). RedHill's ADSs will continue to trade on The Nasdaq Capital Market, and its operations remain unaffected. RedHill is considering options to address the deficiency and may be eligible for an additional 180-day compliance period if necessary conditions are met.